A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma

PURPOSE: The purpose of this study was to investigate the triple-combination therapy of lenvatinib plus sintilimab plus arterially-directed therapy as a conversion therapy for initially unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS: We retrospectively analyzed data from all HCC p...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Leijuan, Lang, Mengran, Tian, Xindi, Ren, Shaohua, Li, Guangtao, Liu, Yayue, Han, Ruyu, Zhu, Kangwei, Li, Huikai, Wu, Qiang, Cui, Yunlong, Zhang, Wei, Fang, Feng, Li, Qiang, Song, Tianqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132469/
https://www.ncbi.nlm.nih.gov/pubmed/37125392
http://dx.doi.org/10.2147/JHC.S404675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132469/
https://www.ncbi.nlm.nih.gov/pubmed/37125392
http://dx.doi.org/10.2147/JHC.S404675

Ejemplares similares